• About us
• Contact

Advertisement

Product › Details

mRNA-based vaccine

	Next higher product group	vaccine

CureVac AG. (12/22/17). "Press Release: CureVac to Present at the 2018 J.P. Morgan 36th Annual Healthcare Conference". Tübingen & Boston, MA.

CureVac to Present at the 2018 J.P. Morgan 36th Annual Healthcare Conference


CureVac AG, a clinical-stage biopharmaceutical company pioneering mRNA-based drugs, will present at the 2018 J.P. Morgan 36th Annual Healthcare Conference to be held January 8-12, 2018 at the Westin St. Francis Hotel in San Francisco, CA. The presentation will be delivered by Ingmar Hoerr, Ph.D., co-founder and CEO of CureVac AG.

Details of CureVac's presentation are as follows:

Event: J.P. Morgan 36th Annual Healthcare Conference
Date: January 10, 2018
Time: 8:00 – 8:25 AM (Pacific Time) / 5:00 - 5:25 PM (Eastern Standard Time)

A live webcast of the presentation will be available here for replay following the event.

Further information on the 2018 J.P. Morgan 36th Annual Healthcare Conference can be found here.


Your contact

Verena Lauterbach
Senior Manager Communications
T: +49 7071 9883 1756
contact via e-mail

Record changed: 2024-04-29

Advertisement

More documents for mRNA-based vaccine

• [1] CureVac N.V.. (4/24/24). "Press Release: CureVac Appoints Thaminda Ramanayake as New Chief Business Officer". Tübingen & Boston, MA....
• [2] CureVac N.V.. (4/16/24). "Press Release: CureVac and MD Anderson Enter Strategic Collaboration to Develop Novel Cancer Vaccines". Tübingen & Houston, TX....
• [3] BioNTech SE. (3/20/24). "Press Release: BioNTech Announces Appointment of Annemarie Hanekamp to Management Board as Chief Commercial Officer". Mainz....
• [4] CureVac N.V.. (1/17/24). "Press Release: CureVac CEO Alexander Zehnder Acquires Common Shares of Company Stock". Tübingen & Boston, MA....
• [5] CureVac N.V.. (1/5/24). "Press Release: CureVac Announces Positive Phase 2 Interim Data from COVID-19 Vaccine Development Program in Collaboration with GSK Providing Strong Validation of Proprietary Technology Platform". Tübingen & Boston, MA....
• [6] CureVac N.V.. (12/19/23). "Press Release: CureVac Announces Decision of German Federal Patent Court in Broad Patent Litigation with BioNTech SE". Tübingen....
• [7] BioNTech SE. (12/18/23). "Press Release: BioNTech Achieves Milestone at mRNA-based Vaccine Manufacturing Site in Rwanda". Kigali....
• [8] CureVac N.V.. (9/28/23). "Press Release: CureVac Reports Progress in Intellectual Property Infringement Case Against BioNTech in Germany". Tübingen & Boston, MA....
• [9] Transimmune AG. (9/20/23). "Press Release: Transimmune Secures $5m Funding to Enhance mRNA Vaccination with Novel Dendritic Cell Therapy". Düsseldorf....
• [10] CureVac N.V.. (8/17/23). "Press Release: CureVac Announces Financial Results for the Second Quarter and First Half of 2023 and Provides Business Update". Tübingen & Boston, MA....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

» top

» Imprint  |  » Data Privacy  |  » Contact  |  The use of this website requires to accept the » Disclaimer!   |  A project of [iito] Business Intelligence © 2002-2024. Made in Germany.